Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars

Introduction Skin scars, a natural outcome of dermal injury healing, may seem minor but often lead to significant disfigurement and psychological distress. This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate. This synergistic formulation targets multiple scar-improvement mechanisms, offering potential for enhanced skin texture and minimized scar appearance. Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars. Ethical approval was granted by the Independent Ethics Committee, and informed consent was obtained from all participants. Visible scar changes were assessed using the Manchester Scoring Scale by a dermatologist. Skin texture changes, including smoothness, roughness, and scaliness, were evaluated using VISIOSCAN® VC20 Plus (Courage + Khazaka electronic GmbH, Cologne, Germany). Digital photographs documented progressive scar visibility reduction. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 29.0.1.0 (Released 2022; IBM Corp., Armonk, New York) and Microsoft® Excel 2019 (Microsoft Corporation, Redmond, Washington), with significance reported at the 5% level. Result The test product reduced scar appearance by 7.17% at day 21 (p<0.001) and 26.57% at day 45 (p<0.0001). Skin smoothness improved by 33.08% at day 21 (p<0.0001) and 44.56% at day 45 (p<0.0001). Skin roughness decreased by 100.86% at day 21 (p<0.0001) and 161.62% at day 45 (p<0.0001). Scaliness reduced by 39.71% at day 21 (p<0.001) and 58.92% at day 45 (p<0.0001). No local or systemic adverse effects were reported. Conclusion ThriveCo Scar Fader Gel with Scarcede™ demonstrated clinical safety and efficacy in scar reduction, supporting smoother, clearer skin without adverse effects and suitable for routine skincare use.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-08-25
DOI
https://doi.org/10.7759/cureus.90934
Primary Topic
Dermatologic Treatments and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars

Maheshvari Patel, Apeksha Merja, Shatakshi Maulekhi, Nayan Patel et al.
Cureus
Dermatologic Treatments and Research
article

Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars

Maheshvari Patel, Apeksha Merja, Shatakshi Maulekhi, Nayan Patel, Saurav Patnaik
article en

Abstract

Introduction Skin scars, a natural outcome of dermal injury healing, may seem minor but often lead to significant disfigurement and psychological distress. This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate. This synergistic formulation targets multiple scar-improvement mechanisms, offering potential for enhanced skin texture and minimized scar appearance. Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars. Ethical approval was granted by the Independent Ethics Committee, and informed consent was obtained from all participants. Visible scar changes were assessed using the Manchester Scoring Scale by a dermatologist. Skin texture changes, including smoothness, roughness, and scaliness, were evaluated using VISIOSCAN® VC20 Plus (Courage + Khazaka electronic GmbH, Cologne, Germany). Digital photographs documented progressive scar visibility reduction. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 29.0.1.0 (Released 2022; IBM Corp., Armonk, New York) and Microsoft® Excel 2019 (Microsoft Corporation, Redmond, Washington), with significance reported at the 5% level. Result The test product reduced scar appearance by 7.17% at day 21 (p<0.001) and 26.57% at day 45 (p<0.0001). Skin smoothness improved by 33.08% at day 21 (p<0.0001) and 44.56% at day 45 (p<0.0001). Skin roughness decreased by 100.86% at day 21 (p<0.0001) and 161.62% at day 45 (p<0.0001). Scaliness reduced by 39.71% at day 21 (p<0.001) and 58.92% at day 45 (p<0.0001). No local or systemic adverse effects were reported. Conclusion ThriveCo Scar Fader Gel with Scarcede™ demonstrated clinical safety and efficacy in scar reduction, supporting smoother, clearer skin without adverse effects and suitable for routine skincare use.

CureusVol. 17(8)
Physical Research Laboratory (IN), Ansal University (IN), Ahmedabad University (IN), Indus University (IN)
Openalex Percentile: Top 61%
Dermatologic Treatments and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.